bestatin | 82864-81-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: bestatin
• 英文别名: 3-Amino-2-hydroxy-4-phenyl-butanoylleucine；(2S)-2-[(3-amino-2-hydroxy-4-phenylbutanoyl)amino]-4-methylpentanoic acid
• CAS: 82864-81-1
• 化学式: C₁₆H₂₄N₂O₄
• 分子量: 308.378
• InChiKey: VGGGPCQERPFHOB-MOKVOYLWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• 3-Amino-2-hydroxy-4-phenylbutanoic acid derivatives and pharmaceutical composition containing the same
  申请人：ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI

  公开号：EP0077274A1

  公开（公告）日：1983-04-20

  New 3-N-acyl derivatives of 3-amino-2-hydroxy-4-phenylbutanoic acid are provided, which exhibit analgesic activity and are effective to enhance the morphine analgesia.

  本研究提供了 3-氨基-2-羟基-4-苯基丁酸的 3-N-acyl 新衍生物，它们具有镇痛活性，能有效增强吗啡镇痛效果。
• New bestatin-related compounds as immunopotentiator
  申请人：ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI

  公开号：EP0083931A2

  公开（公告）日：1983-07-20

  3-Amino-2-hydroxy-4-phenylbutanoyl-leucyl-asparagines which are related to bestatin in their chemical structure and which are active to enhance the immune response in living animals are now provided.

  3-Amino-2-hydroxy-4-phenylbutanoyl-leucyl-asparagines 与 bestatin 的化学结构有关，具有增强活体动物免疫反应的活性。
• PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PALLIATION OF ELDERLY OR END-STAGE CANCER PATIENT
  申请人：Delta-Fly Pharma, Inc.

  公开号：EP3235505A1

  公开（公告）日：2017-10-25

  An object of the present invention is to provide a novel treatment method with fewer side effects for elderly cancer patients and terminal cancer patients. A pharmaceutical composition for treating or putting an elderly or a terminal cancer patient into remission, comprising, as an active ingredient, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof.

  本发明的目的是为老年癌症患者和晚期癌症患者提供一种副作用较少的新型治疗方法。一种用于治疗老年癌症患者或晚期癌症患者或使其病情得到缓解的药物组合物，其活性成分包括(2S)-2-[(2S,3R)-3-氨基-2-羟基-4-苯基丁酰氨基]-4-甲基戊酸或其药理学上可接受的盐。
• PHARMACEUTICAL COMPOSITION FOR TREATMENT OR REMISSION OF CHRONIC MYELOGENOUS LEUKEMIA
  申请人：Delta-Fly Pharma, Inc.

  公开号：EP3527211A1

  公开（公告）日：2019-08-21

  The present application provides a pharmaceutical composition for use in treatment or remission of patients with chronic myelogenous leukemia, wherein the composition comprises, as active ingredients, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide or a pharmacologically acceptable salt thereof, both of which are used at low doses.

  本申请提供了一种用于治疗或缓解慢性骨髓性白血病患者的药物组合物，其中组合物作为活性成分包括(2S)-2-[(2S、 3R)-3-氨基-2-羟基-4-苯基丁酰氨基]-4-甲基戊酸或其药理上可接受的盐，以及 4-[(4-甲基-1-哌嗪基)甲基]-N-[4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]苯基]-苯甲酰胺或其药理上可接受的盐，这两种药物均以低剂量使用。
• URINE ALKALI AGENT USEFUL FOR TREATMENT OF CANCER PATIENT
  申请人：Delta-Fly Pharma, Inc.

  公开号：EP3741365A1

  公开（公告）日：2020-11-25

  An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

  本发明的目的是提供一种治疗/缓解癌症和预防癌症复发/转移的高效方法，成本低，副作用小。一种含有尿碱化剂的组合物，用于治疗或缓解癌症，或预防癌症复发或转移。